| Dr Mayur Movalia, MD | |
|
417 State St, Webber West, Suite 541, Bangor, ME 04401-6630 | |
| (207) 941-8200 | |
| Not Available |
| Full Name | Dr Mayur Movalia |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 28 Years |
| Location | 417 State St, Bangor, Maine |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639396690 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZH0000X | Pathology - Hematology | MD17475 (Maine) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Eastern Maine Medical Center | Bangor, ME | Hospital |
| St Joseph Hospital | Bangor, ME | Hospital |
| Redington Fairview General Hospital | Skowhegan, ME | Hospital |
| A R Gould Hospital | Presque isle, ME | Hospital |
| Northern Light Mercy Hospital | Portland, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dahl Chase Pathology Associates Pa | 8820995947 | 15 |
News Archive
In a development that could have great significance for efforts to understand how the basic molecular machinery of life works, researchers at the University of Texas Medical Branch at Galveston (UTMB) have successfully applied an innovative computer modeling technique to predicting how protein molecules will behave in response to different environmental conditions.
Researchers at Mount Sinai School of Medicine have gained insight into the mechanism by which a pathological brain protein called tau contributes to the progression of Alzheimer's disease (AD) and other neurodegenerative disorders. This finding, published in the most recent issue of the Journal of Biological Chemistry, may provide the basis for future investigations on how to prevent tau from damaging brain circuits involved in cognitive function.
YM BioSciences Inc., is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.
A small disposable vibrating device may help detect peripheral sensory neuropathy in patients with diabetes, say UK researchers who believe the gadget could replace tuning fork screening.
"N60" might not be the first thing that comes to mind when people think of Alzheimer's disease, but thanks to researchers from the United States, South Korea and France, this might change. That's because these researchers have found that the N60 section of a protein called "RanBP9" might be the key that unlocks an entirely new class of Alzheimer's drugs, and with them, hope. In a research report published online in The FASEB Journal, these scientists describe how the N60 fragment of the RanBP9 protein increases the production of the amyloid beta protein, which is present in excessive amounts in the brains of people with Alzheimer's disease.
› Verified 1 days ago
| Entity Name | Dahl Chase Pathology Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992726913 PECOS PAC ID: 8820995947 Enrollment ID: O20031217000381 |
News Archive
In a development that could have great significance for efforts to understand how the basic molecular machinery of life works, researchers at the University of Texas Medical Branch at Galveston (UTMB) have successfully applied an innovative computer modeling technique to predicting how protein molecules will behave in response to different environmental conditions.
Researchers at Mount Sinai School of Medicine have gained insight into the mechanism by which a pathological brain protein called tau contributes to the progression of Alzheimer's disease (AD) and other neurodegenerative disorders. This finding, published in the most recent issue of the Journal of Biological Chemistry, may provide the basis for future investigations on how to prevent tau from damaging brain circuits involved in cognitive function.
YM BioSciences Inc., is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.
A small disposable vibrating device may help detect peripheral sensory neuropathy in patients with diabetes, say UK researchers who believe the gadget could replace tuning fork screening.
"N60" might not be the first thing that comes to mind when people think of Alzheimer's disease, but thanks to researchers from the United States, South Korea and France, this might change. That's because these researchers have found that the N60 section of a protein called "RanBP9" might be the key that unlocks an entirely new class of Alzheimer's drugs, and with them, hope. In a research report published online in The FASEB Journal, these scientists describe how the N60 fragment of the RanBP9 protein increases the production of the amyloid beta protein, which is present in excessive amounts in the brains of people with Alzheimer's disease.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mayur Movalia, MD 417 State St Ste 541, Bangor, ME 04401-6635 Ph: (207) 941-8200 | Dr Mayur Movalia, MD 417 State St, Webber West, Suite 541, Bangor, ME 04401-6630 Ph: (207) 941-8200 |
News Archive
In a development that could have great significance for efforts to understand how the basic molecular machinery of life works, researchers at the University of Texas Medical Branch at Galveston (UTMB) have successfully applied an innovative computer modeling technique to predicting how protein molecules will behave in response to different environmental conditions.
Researchers at Mount Sinai School of Medicine have gained insight into the mechanism by which a pathological brain protein called tau contributes to the progression of Alzheimer's disease (AD) and other neurodegenerative disorders. This finding, published in the most recent issue of the Journal of Biological Chemistry, may provide the basis for future investigations on how to prevent tau from damaging brain circuits involved in cognitive function.
YM BioSciences Inc., is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.
A small disposable vibrating device may help detect peripheral sensory neuropathy in patients with diabetes, say UK researchers who believe the gadget could replace tuning fork screening.
"N60" might not be the first thing that comes to mind when people think of Alzheimer's disease, but thanks to researchers from the United States, South Korea and France, this might change. That's because these researchers have found that the N60 section of a protein called "RanBP9" might be the key that unlocks an entirely new class of Alzheimer's drugs, and with them, hope. In a research report published online in The FASEB Journal, these scientists describe how the N60 fragment of the RanBP9 protein increases the production of the amyloid beta protein, which is present in excessive amounts in the brains of people with Alzheimer's disease.
› Verified 1 days ago
Chung Ho Shum, M.D., PH.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 417 State St, Webber West 541, Bangor, ME 04401 Phone: 207-941-8200 | |
Lindsay Williams, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 417 State St Ste 439, Bangor, ME 04401 Phone: 207-941-8200 Fax: 207-947-4061 | |
Ian Mukand-cerro, M.D. Pathology Medicare: Medicare Enrolled Practice Location: 417 State St Ste 439, Bangor, ME 04401 Phone: 207-941-8200 Fax: 207-990-4848 | |
Dr. Kevin M Kitagawa, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 417 State St, Suite 439, Bangor, ME 04401 Phone: 207-941-8200 Fax: 207-990-4848 | |
Hong Jiang, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 417 State St Ste 349, Bangor, ME 04401 Phone: 207-941-8200 Fax: 207-947-4061 | |
Rima Kanhoush, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 417 State St Ste 439, Bangor, ME 04401 Phone: 207-941-8200 Fax: 207-990-4848 |